Drug Pipeline

NME: Chemotherapy agent to be used in combination for recurrent colorectal cancer

Tegaserod maleate (Zelnorm) is the first selective partial 5-HT4 agonist approved by FDA for the short-term treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is constipation. To help you prepare for P & T Committee review, this article presents tegaserod?s chemistry and pharmacology, pharmacokinetics, clinical trial results, adverse effects profile, dosing information, cost, and the author?s opinion on its place in therapy.

With enoxaparin?s recent labeling change regarding its use in patients with prosthetic valves, clinicians may have several questions about appropriate anticoagulant selection. Specifically, what evidence prompted the labeling change, which patients are affected, what are the options and limitations for bridging patients, what?s the evidence supporting the role of low molecular weight heparins (LMWHs) in bridge therapy, and how can liability be limited should clinicians choose to use LMWH therapy? The authors of this commentary offer their insight on these issues.

Instead of adopting a Medicare pharmacy benefit plan in July, the Senate approved legislation designed to make pharmaceuticals less expensive for all consumers. The House and Senate, however, remain far from agreement on any final legislation involving pharmaceutical coverage and regulation, and time is running out for action before the Congressional elections this November.

ARB now indicated for heart failure

In late May, voriconazole (Vfend) received approval for the treatment of invasive aspergillosis and as salvage therapy for treatment of Scedosporium apiospermum and Fusarium infections. In addition to these infections, voriconazole has excellent invitro activity against both Candida and Aspergillus species, including good activity against fluconazole- and itraconazole-resistant species. This Focus article reviews the antifungal's pharmacology, pharmacokinetics, efficacy in clinical trials, safety, dosing, price, and place in therapy.

Effective decision-making in benefit management requires an understanding of the economic burden of an illness - in this case, the economic burden and treatment of alcoholism. This article provides an understanding of the true costs of the disease, what has been found to be effective in its treatment, and what treatments may lessen the economic burden of the disease.

Finding optional ways to manage patients with chronic obstructive pulmonary disease (COPD) - the fourth leading cause of death in the US became a priority for this large mid-western collaborative of health care organizations. This this end, a guideline was developed to help clinicians identify, evaluate and manage COPD. This article provides an overview of the guideline development process and implementation approach, key guideline components, and the step-by-step pharmacologic treatment strategy.

Just before leaving Washington for the Memorial Day recess in May, Congress approved legislation to enhance the ability of hospitals and public health agencies to respond to bioterrorist threats.

Patients with Crohn's disease who show an initial response to a single dose of infliximab (Remicade) are more likely to remain in remission a year later if therapy is maintained every 8 weeks, say these researchers.

Three case-controlled studies published in the Archives of Internal Medicineshow naproxen sodium has cardioprotective effects that other NSAIDs don't.An accompanying editorial says that no evidence indicates that the COX-2inhibitor rofecoxib increases (or decreases) MI risk. It simply fell victimto being compared with the only NSAID (ie, naproxen) shown to have a cardioprotectivebenefit. (None of these new studies directly compared non-naproxen NSAIDswith COX-2 inhibitors.)

Just before leaving Washington for the Memorial Day recess in May, Congress approved legislation to enhance the ability of hospitals and public health agencies to respond to bioterrorist threats. A key addition to the bill reauthorizes the Prescription Drug User Fee Act (PDUFA) for 5 years so that the Food and Drug Administration will continue to accelerate development and approval of new drugs.

Tegaserod, an investigational serotonin receptor agonist, provides global relief of the symptoms of constipation-predominant irritable bowel syndrome (IBS) with an acceptable incidence of adverse events, according to the results of meta-analysis of four phase III trials presented at Digestive Disease Week in San Francisco.

New Indications: First approval of oral treatment for postherpetic neuralgia

NME: Option for life-threatening fungal infections

NME: Approved for all symptomatic stages of pulmonary arterial hypertension

New labeling for the cholesterol-loweringagent simvastatin (Zocor, Merck) highlights the risks of myopathyand rhabdomyolysis with or without acute renal failure as side effectsof the drug alone or in combination.

Confusion between two drugs with sound-alike proprietary names, the antipsychotic quetiapine fumarate (Seroquel, AstraZeneca) and antidepressant nefazodone HCl (Serzone, Bristol-Meyers Squibb) has prompted AstraZeneca to send a "Dear Healthcare Professional" letter warning of the potential mix-up.

Cases of uterine sarcoma in women receiving tamoxifen citrate (Nolvadex, AstraZeneca) have prompted a "Dear Health Professional" letter, black-box warnings on labeling, and publication of a letter to the editor in the New England Journal of Medicine from FDA officials.

A black-boxwarning added to baclofen's (Lioresal Intrathecal, Med-tronic) labelingwarns against abrupt discontinuation of the drug.

Safety information from the Celecoxib Long-term Arthritis Safety Study (CLASS)on GI and cardiovascular events has been included in safety labeling forcelecoxib (Celebrex, Searle).

Ever since troglitazone was pulled from the market because of hepatotoxicity,clinicians has been concerned that this may be a class effect. But a newstudy of rosiglitazone (Avandia), funded by manufacturer SmithKlineBeecham,indicates this drug is not associated with heptatotoxic effects.

Previous observational studies found that starting statins early after an MI reduces the risk of second heart attacks and death. But a new, larger observational study published last month in JAMA found no such reduction with early initiation (< 7 days)-and even an increased risk of MI or death for patients whose cholesterol levels were below treatment guideline levels.

The evidence doesn't support a link between administration of hepatitis B (HPB) vaccine and demyelinating disorders, such as multiple sclerosis (MS) and Guillain-Barré syndrome, so no change in immunization policy is warranted, according to an Institute of Medicine (IOM) report.

Eplerenone, a selective aldosterone inhibitor in phase III clinical trials,is an effective agent for reducing blood pressure in a variety of patientswith hypertension, including African-Americans, said presenters at the 17thannual scientific meeting of the American Society of Hypertension in NewYork City.